Context Therapeutics Showcases CTIM-76 at Major Oncology Meeting
Context Therapeutics Inc. (Nasdaq: CNTX), a pioneering biopharmaceutical firm focused on developing T cell engagers for the treatment of solid tumors, has announced an exciting opportunity to present clinical data on their innovative asset, CTIM-76. This presentation will take place during a significant oncology event, the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting. The meeting is set to occur at the George R. Brown Convention Center, where this vital research will be unveiled to a wide audience of professionals in the field.
Details of the Presentation
The spotlight will shine on a poster detailing the first human dosing of CTIM-76, a bispecific antibody engineered to engage T cells and target Claudin 6, an important marker in various solid tumors. This session is particularly relevant as it encapsulates the potential of bispecific therapies in improving treatment outcomes for patients. Interested attendees can learn more about the session, which is scheduled for Saturday at 9:00 AM CDT.
Title and Authors of the Presentation
The title of this pivotal presentation is "Determination of first in human dose of the T cell-redirecting bispecific antibody CTIM-76 targeting Claudin 6." The research has been conducted by a talented team including Kelly Byrnes-Blake, Ed Calamai, Stanley Roberts, and Eric Butz, who have devoted considerable effort to advancing the understanding of CTIM-76.
Location and Abstract Number
This notable presentation is being assigned the abstract number 1288 and will take place in Exhibit Halls AB, allowing for engaging discussions among specialists and industry leaders during the event.
Understanding CTIM-76
CTIM-76 represents a significant advancement in cancer therapy, being a Claudin 6 x CD3 T cell engaging bispecific antibody. This compound holds promise for treating a range of solid tumors, including those in the ovaries, lungs, and testicles. Grounded in preclinical research, CTIM-76 has demonstrated advantages for patients, including ease of administration, low immunogenicity risk, and the potential for large-scale manufacturing, making it an attractive therapy option as interest in personalized medicine grows.
About Context Therapeutics Inc.
Context Therapeutics Inc. (Nasdaq: CNTX) is on a path to revolutionize cancer treatment through innovative T cell engaging bispecific antibodies. Their portfolio includes several promising candidates: CTIM-76, alongside CT-95, targeting Mesothelin, and CT-202, aimed at Nectin-4. Context’s headquarters in Philadelphia serves as a hub for their groundbreaking research and development efforts, ensuring that they remain at the forefront of cancer therapeutics.
Stay Updated with Context Therapeutics
For those wishing to keep in touch and learn more about the innovative work being done at Context Therapeutics, visiting their official website will provide updates on ongoing research and advancements. Additionally, you can follow the Company on social media platforms such as X and LinkedIn to receive the latest news directly from the source.
Frequently Asked Questions
What is CTIM-76?
CTIM-76 is a bispecific antibody developed by Context Therapeutics that targets Claudin 6, which is prevalent in certain solid tumors, to engage T cells in the fight against cancer.
When will the presentation take place?
The presentation is scheduled for Saturday at 9:00 AM CDT during the SITC 39th Annual Meeting.
Who are the authors of the research presented?
The research features contributions from authors Kelly Byrnes-Blake, Ed Calamai, Stanley Roberts, and Eric Butz.
Where is the SITC Annual Meeting being held?
The SITC 39th Annual Meeting will be held at the George R. Brown Convention Center.
How can I stay informed about Context Therapeutics?
You can visit the official Context Therapeutics website and follow them on platforms like X and LinkedIn for the latest updates and information.
